Coya Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
COYA$2.99+6.4%Stored close · as of Nov 6, 2026
Contents
Item 1. Financial Statements
CONDENSED BALANCE SHEETS
| (unaudited) | ||
|---|---|---|
| March 31, | December 31, | |
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $50,724,643 | $46,822,786 |
| Prepaids and other current assets | 2,538,036 | 3,116,232 |
| Total current assets | 53,262,679 | 49,939,018 |
| Fixed assets, net | 8,420 | 11,227 |
| Total assets | $53,271,099 | $49,950,245 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $948,192 | $1,061,122 |
| Accrued expenses | 1,355,714 | 3,612,913 |
| Deferred collaboration revenue | 1,242,635 | 1,197,856 |
| Total current liabilities | 3,546,541 | 5,871,891 |
| Deferred collaboration revenue | 754,198 | 1,050,124 |
| Total liabilities | 4,300,739 | 6,922,015 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' equity: | ||
| Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued or outstanding as of March 31, 2026 or December 31, 2025 | - | - |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 23,457,183 and 20,934,456 shares issued and outstanding as of March 31, 2026 or December 31, 2025, respectively | 2,346 | 2,094 |
| Additional paid-in capital | 118,138,281 | 104,989,413 |
| Accumulated deficit | (69,170,267) | (61,963,277) |
| Total stockholders' equity | 48,970,360 | 43,028,230 |
| Total liabilities and stockholders' equity | $53,271,099 | $49,950,245 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.